What is the efficacy of lenalidomide (Revlimid) for the treatment of renal cell carcinoma (RCC)?

Updated: May 21, 2019
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print
Answer

The immunomodulator lenalidomide (Revlimid), a derivative of thalidomide, inhibits vascular endothelial growth factor (VEGF), stimulates T and natural killer (NK) cells, and inhibits inflammatory cytokines. This agent has been evaluated extensively in hematologic malignancies. In phase 2 studies of metastatic renal cell carcinoma, lenalidomide demonstrated an antitumor effect in some cases, with disease stabilization or durable partial response. [67, 68]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!